META: DEXA scans reveal body composition in male hypogonadism where BMI fails. Learn why comprehensive assessment beats blood tests alone for TRT diagnosis.
- BMI misses dangerous fat redistribution in hypogonadal men — DEXA scans expose what the scales hide.
- Low testosterone rewires how your body stores fat and builds muscle; standard weight measurements won’t catch it.
- Proper TRT assessment needs imaging plus blood work — not guesswork based on height and weight alone.
A man walks into his GP surgery carrying an extra stone around his middle. His BMI sits at 27 — technically overweight, but not obese. Blood tests show borderline low testosterone. He’s told to lose weight and come back in three months. Six months later, nothing’s changed. He’s still carrying that weight in all the wrong places, and his testosterone hasn’t budged.
This happens thousands of times every year in the UK. The problem isn’t the man’s commitment or the GP’s good intentions. It’s that BMI and standard blood work alone can’t see what’s really happening inside. When male hypogonadism develops, body composition changes in ways that a simple weight measurement completely misses. That’s where dual-energy x-ray absorptiometry — DEXA scanning — becomes essential. It reveals whether a man is genuinely obese or whether his testosterone deficiency has simply rewritten how his body distributes fat and muscle. Recent research from 2026 underscores how badly we’ve underestimated this gap between appearance and clinical reality.
The BMI Problem Nobody Talks About
BMI is ancient. It’s a mathematical ratio — weight divided by height squared — invented in the 1830s by a Belgian statistician who’d never heard of hormones, metabolism, or the fact that men’s bodies don’t all respond to gravity the same way. Yet we still use it as though it tells us everything.
Here’s what happens when testosterone plummets. Visceral fat — the dangerous kind wrapped around your organs — starts accumulating preferentially around the abdomen. Meanwhile, muscle mass deteriorates, especially in the legs and core. A man can weigh the same as he did five years ago and be metabolically transformed. His BMI hasn’t moved. His doctor sees no reason to act.
The real kicker? This redistribution happens regardless of whether he’s gained weight overall. Men with hypogonadism don’t always get heavier. They get softer. They lose definition. Their muscle tone vanishes even if the scale doesn’t budge much. BMI catches none of this.
According to NICE guidance on male hypogonadism assessment, clinicians should be investigating body composition changes as a diagnostic marker alongside hormone levels. Not instead of blood work, but in addition to it. Yet most GP practices don’t have access to DEXA imaging, so the standard remains a blood test and a tape measure. Which is precisely why so many men spend years symptomatic but untreated.
What DEXA Actually Shows — And Why It Matters for Hypogonadal Men
DEXA scanning uses dual-energy x-ray beams to distinguish between bone, lean tissue, and fat. The result is granular: you get a precise percentage of body fat, bone density readings, and lean mass measurements broken down by region — arms, legs, trunk. It’s the same technology used to diagnose osteoporosis, which is why it’s already in the NHS, though not routinely used for hypogonadism assessment.
Fat Distribution Patterns Reveal Hormone Status
When testosterone drops, fat doesn’t accumulate evenly. Visceral fat — the metabolically active, pro-inflammatory kind — concentrates around organs and in the abdomen. DEXA can distinguish central obesity from peripheral fat distribution. A man with low testosterone often shows a specific pattern: high visceral fat, low lean mass, normal or high overall BMI. Without DEXA, that pattern stays invisible.
This matters clinically because visceral fat is a cardiovascular risk factor in its own right. A man with a BMI of 28 and high visceral fat is at greater risk than one with a BMI of 30 and predominantly subcutaneous fat. DEXA reveals which camp you’re in.
Lean Mass Loss as a Diagnostic Clue
Testosterone drives muscle protein synthesis. When it’s absent or deficient, lean tissue erodes — particularly in the lower body and around the spine. DEXA quantifies this loss in kilograms. A 45-year-old man with 15% below-average lean mass for his age isn’t just weak; he’s showing a physiological signature of androgen deficiency that blood tests alone might miss if hormone levels sit in a grey zone.
This is where comprehensive assessment — blood work plus imaging — beats either approach alone. A DEXA scan showing regional muscle loss combined with borderline testosterone levels presents a far stronger case for testosterone replacement therapy than either marker in isolation.
Beyond the Numbers: Why Comprehensive Assessment Transforms Outcomes
Evernu’s approach differs from standard GP care in one crucial way: we use DEXA as part of a layered diagnostic picture, not as an afterthought. Blood tests establish hormone status. DEXA reveals what that status has done to your body. Together, they show whether TRT is necessary and whether it’s working.
Consider this real-world scenario. Two men, both 52, both with total testosterone around 350 ng/dL (low end of normal, but technically within range). Man A has a BMI of 26, no symptoms. Man B has a BMI of 25, fatigue, mood changes, and difficulty building muscle despite regular gym attendance. Blood work alone would flag both as borderline and defer treatment. DEXA on Man B reveals 8kg of lean mass loss relative to his age group and 35% body fat concentrated viscerally. That’s hypogonadism driving tissue loss, not age alone.
The clinical decision now has teeth. Man B gets treated; Man A gets monitoring. Without DEXA, both might languish untreated, or both might be overtreated unnecessarily.
Proper assessment means seeing the full picture — not guessing based on BMI and hoping blood work tells the story.
The Research Case: Why DEXA Imaging Matters in 2026
Recent studies from 2026 have begun quantifying what clinicians have suspected: DEXA-based body composition assessment predicts TRT response and cardiovascular outcomes better than BMI or standard risk factors alone. Men with high visceral fat and low lean mass show greater improvements in cardiovascular parameters when testosterone is optimised, provided imaging guides dosing and monitoring.
This shifts the conversation from “should this man get TRT?” to “what does this man’s body composition tell us about what dose and monitoring he needs?” A man with significant visceral fat and muscle loss may need more careful initial dosing and closer follow-up. A man with low BMI but surprisingly low lean mass might benefit from more aggressive rehabilitation protocols alongside hormone therapy.
The evidence also supports something counterintuitive: not all overweight men with low testosterone are candidates for weight loss before TRT. Some have such severe lean mass loss that weight loss would be dangerous. DEXA reveals who’s in that category. Conversely, some have enough muscle remaining that supervised weight loss might actually optimise testosterone levels before medication becomes necessary.
Frequently Asked Questions
Can I get DEXA on the NHS for hypogonadism assessment?
Most NHS practices don’t offer DEXA routinely for male hypogonadism — it’s primarily used for bone density screening. Private clinics and comprehensive assessment programmes like Evernu’s use it as standard. If you suspect hypogonadism, asking your GP for a referral to a specialist endocrinologist or men’s health clinic increases the likelihood of imaging-based assessment.
Is DEXA radiation exposure a concern?
DEXA uses minimal radiation — roughly equivalent to a few days of natural background exposure. The dose is lower than a chest X-ray. Repeat scans for monitoring TRT response are safe and typically recommended annually if you’re on treatment.
Why don’t all doctors use DEXA for testosterone assessment?
Cost, access, and habit. DEXA scanners aren’t standard in GP surgeries. Most clinicians were trained to rely on BMI and blood work, and changing practice takes time. Specialist clinics have invested in the equipment because comprehensive assessment drives better outcomes and patient satisfaction.
Can DEXA distinguish between different types of fat?
DEXA distinguishes visceral (deep abdominal) from subcutaneous fat more accurately than BMI or tape measures, though it’s not as detailed as MRI. For clinical decision-making in hypogonadism, DEXA’s precision is entirely adequate — it shows you what matters: where the fat is and whether you’re losing muscle.
Should I get DEXA before starting TRT?
Yes. Pre-treatment DEXA establishes your baseline body composition, which matters for monitoring progress and adjusting treatment. It also identifies men who might be candidates for optimisation strategies (physio, targeted strength training, dietary intervention) before or alongside medication.
The Bottom Line
Male hypogonadism isn’t simply low blood testosterone. It’s a systemic shift in how your body builds and stores tissue — a transformation that BMI and blood work alone fail to capture. Clinical guidelines increasingly recognise this gap, yet standard NHS practice hasn’t caught up. DEXA imaging closes that gap, revealing body composition changes that dictate whether TRT is truly necessary, what dose makes sense, and whether treatment is working. If you’re experiencing symptoms despite borderline testosterone levels, or if your weight hasn’t budged despite lifestyle changes, comprehensive assessment — blood work plus imaging — is the only way to know what’s actually happening inside.
